SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. (“Design” or the “Company”) (NASDAQ: DSGN). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Design and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On or around March 24, 2021, Design conducted its initial public offering (“IPO”), selling 12 million shares of stock priced at $20.00 per share. Then, on December 7, 2022, Design reported initial data from a Phase 1 trial of DT-216 in patients with Friedreich ataxia. Among other results, Design said 16 patients on DT-216 and eight on placebo reported at least one treatment-emergent adverse event. On this news, Design’s stock price fell sharply during intraday trading on December 8, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980